Washington D.C., February 19, 2026 (PAHO) – In 2025, the Pan American Health Organization’s Regional Revolving Funds (RFF) delivered over 234 million vaccine doses and 13 million diagnostic tests to countries across the Americas. The supplies reached an estimated 85 million people, helping prevent outbreaks, vaccine-preventable diseases, and avoidable deaths, according to consolidated data for the year.
Through these pooled procurement mechanisms, countries secured over US$900 million in health supplies at affordable prices, generating savings often of around 50% on many public health supplies, allowing countries to stretch limited health budgets while ensuring timely access to supplies, including during emergencies.
“The Regional Revolving Funds continue to adapt to the evolving needs of our Member States, making cutting-edge vaccines, treatments, and diagnostics more accessible and affordable,” said PAHO Director Dr. Jarbas Barbosa. “By working together, countries strengthen supply security, reduce dependency on external sources, and advance disease prevention and elimination for all.”
Nearly every country and territory in the Americas, with the exception of Canada and the United States, along with nine Caribbean territories, two subnational entities, and seven public institutions, accessed supplies through the Funds.
A key achievement in 2025 was the region’s progress in local manufacturing. While only 1.5% of RRF procurement came from regional producers in 2020, long‑term agreements established in recent years have raised that figure to 23%, with capacity expected to reach 40% in the near term. This shift aims to strengthen supply security and reduce dependency on external manufacturers and global supply disruptions.
Countries also expanded their use of new products made available through the Funds, including malaria treatments and testing, telehealth devices, dengue and RSV vaccines, the 9-valent HPV vaccine for cervical cancer prevention, an increased selection of high‑cost medicines and pediatric cancer treatments, as well as new diagnostics and treatments for advanced HIV disease and tuberculosis.
New supply arrangements allowed PAHO to reserve doses in advance, supporting rapid action during yellow fever and measles outbreaks. Procurement of high-cost medicines also generated substantial savings, with negotiated agreements offering up to 90% reductions for treatments for breast cancer, prostate cancer, multiple sclerosis, and Gaucher disease.
Demand for health supplies connected to PAHO’s Elimination Initiative grew significantly, with a 20% increase in HIV and viral hepatitis diagnostic tests and 10 million additional malaria tests, twice the 2024 volume.
Twelve countries procured essential equipment through the mechanism, including maternal and neonatal technologies, ambulances, cold‑chain systems, TB diagnostic machines, cardiovascular devices, and cervical cancer screening and treatment tools, as well as telehealth devices.
The Funds’ efficiency continued to improve through the digital Member States Portal, which now has more than 530 users from ministries of health and processed over 200 country demand plans, a 30% increase from 2024.
The PAHO Regional Revolving Funds—comprising the Revolving Fund for Access to Vaccines (operating for more than 40 years) and the Strategic Fund for Public Health Supplies—are technical cooperation mechanisms that pool demand, leverage economies of scale, and negotiate transparently with suppliers. This approach lowers costs, strengthens national immunization and health programs, and supports disease control, elimination, and emergency response across the Americas.
